Sweden’s Karo Pharma AB has expanded its consumer healthcare portfolio by acquiring the European rights to the Pevaryl antifungal brand from Johnson & Johnson’s Cilag GmbH business for €58m ($62.7m).
Karo Pharma Grabs J&J’s Pevaryl Brand In Europe
Karo has picked up the full European rights to the Pevaryl antifungal brand from Johnson & Johnson.
